# US FDA LIFTS CLINICAL HOLD ON BHARAT BIOTECH'S COVID VACCINE COVAXIN 

Relevant for: Science \& Technology | Topic: Biotechnology, Genetics \& Health related developments

Bharat Biotech's Covaxin will be evaluated as a Covid vaccine candidate in the United States, the company informed on Saturday.

Ocugen, Inc announced that the US Food and Drug Administration (FDA) has lifted its clinical hld on the company's investigational new drug application to evaluate the Covid vaccine candidate, BB152, known as Covaxin outside the US, Bharat Biotech said in a statement.

COVAXIN will be evaluated as a COVID-19 vaccine candidate in the United States. \#COVID19 \#COVAXIN \#VaccineMandate \#BharatBiotech \#bbv152 \#COVID \#clinicaltrial \#Pandemic pic.twitter.com/nIWWDUKhvW

Ocugen is co-developing Bharat Biotech's Covaxin vaccine for Covid in US and Canada.

Never miss a story! Stay connected and informed with Mint. Download our App Now!!
Log in to our website to save your bookmarks. It'll just take a moment.
Oops! Looks like you have exceeded the limit to bookmark the image. Remove some to bookmark this image.

Your session has expired, please login again.
You are now subscribed to our newsletters. In case you can't find any email from our side, please check the spam folder.

This is a subscriber only feature Subscribe Now to get daily updates on WhatsApp

## END

